HCC1806 - Cell Line (ID:50211)

HMS LINCS ID: 50211
Name: HCC1806
Alternative Names: HCC-1806
LINCS ID: LCL-1960
Alternative ID: CLO_0003644
Parent Cell Line:
Reference Source: ATCC CRL-2335
Organism: Homo sapiens
Organ: breast
Tissue:
Cell Type:
Details of Cell Type:
Donor Sex: female
Donor Age:
Donor Ethnicity:
Donor Health Status:
Disease: DOID:7459, primary acantholytic squamous cell carcino
Details of Disease: breast ductal carcinoma
Production Details:
Genetic Modification(s): none
Known Mutations:
Citation Information for Mutations: COSS907047
Verification Reference Profile:
Growth Properties: adherent
Recommended Culture Conditions: From MGH/CMT as specified by cell provider: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10%. Subculturing: Remove medium, rinse with 0.25% trypsin, 0.03% EDTA solution, add an additional 1 to 2 ml of trypsin solution and allow the flask to set at room temperature (or incubate at 37C) until cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Relevant Citations:
Usage Note:
Comments:
Date Publicly Available: 2012-07-31
Most Recent Update: 2016-04-04

Datasets:

HMS Dataset ID Dataset Title HMS Dataset Type
20120
Metrics other than potency reveal systematic variation in responses to cancer drugs
Analysis
20137
Basal profile of receptor tyrosine kinase signaling network measured by ELISA
ELISA
20138
Cell signaling response to growth factors measured by high throughput microscopy
Microscopy/Imaging
20139
Cell signaling response to cytokines measured by high throughput microscopy
Microscopy/Imaging
20140
Cell signaling response to growth factors measured by ELISA
ELISA
20268
Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates.
Analysis
20269
Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics.
Analysis
20343
Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values
Microscopy/Imaging
20344
Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics
Analysis
20348
Breast Cancer Profiling Project, Gene Expression 1: Baseline mRNA sequencing on 35 breast cell lines
RNA-Seq
20350
Breast Cancer Deubiquitinating Enzyme (DUB) Inhibitor Profiling: Fixed-cell GR measures of 21 breast cell lines to 32 small molecule perturbagens. Dataset 1 of 2: Normalized growth rate inhibition values.
Microscopy/Imaging
20351
Breast Cancer Deubiquitinating Enzyme (DUB) Inhibitor Profiling: Fixed-cell GR measures of 21 breast cell lines to 32 small molecule perturbagens. Dataset 2 of 2: Calculated dose response metrics.
Analysis
20352
Breast Cancer Profiling Project – Proteomics 1: 1 total proteome dataset for a 35-cell line breast cancer panel under basal conditions
Proteomics
20353
Breast Cancer Profiling Project – Proteomics 2: 1 phosphoproteome dataset (including phosphotyrosine enrichment) for a 35-cell line breast cancer panel under basal conditions
Proteomics
20354
Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values
Microscopy/Imaging
20355
Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics
Analysis
20364
Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values.
Microscopy/Imaging
20365
Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics.
Analysis
20366
Evaluation of the sensitivity of two triple-negative breast cancer cell lines (HCC1806, HCC70) to a collection of dual mTOR and PI3K-like kinase (PIKK) inhibitors. Dataset 1 of 2: GR values.
Microscopy/Imaging
20367
Evaluation of the sensitivity of two triple-negative breast cancer cell lines (HCC1806, HCC70) to a collection of dual mTOR and PI3K-like kinase (PIKK) inhibitors. Dataset 2 of 2: GR metrics.
Analysis
20372
mRNA-seq gene expression data for seven cell lines treated with one of three CDK4/6 inhibitors at 0.3, 1.0, or 3.0 μM for 6 or 24 hours
RNA-Seq
20373
DGE-seq Gene expression data for 7 breast cancer cell lines treated with abemaciclib, palbociclib, ribociclib at 0.1, 0.3, 1, or 3 μM, or alvocidib at 0.1 or 1 μM for 6 hours
RNA-Seq

Batch Information:

HMS LINCS Batch ID Provider Provider Catalog ID Provider Batch ID
50211-1 ATCC CRL-2335
50211-2 ATCC CRL-2335